乳腺癌局部区域复发质子再照射的患者选择与毒性预测因素
肋骨骨折发生率21.1%,与首次及再照射胸壁D200cc和首次肋骨D10cc相关。
要点
- 质子再照射后2年及3年任意复发率为14%和17%,总生存率为100%和95%。
- 急性G2和G3不良事件发生率分别为50%和7%,晚期分别为34%和10%。
- 肋骨骨折发生率21.1%,与首次及再照射胸壁D200cc和首次肋骨D10cc相关。
核心结论
- 在迄今最大样本的乳腺癌孤立局部区域复发质子束再照射经验中,尽管患者队列高危,仍观察到有希望的疾病控制和有限的严重不良事件。
- 提供的剂量指标可作为再照射剂量约束的基础,并在未来再照射研究中进一步细化。
研究设计与样本
- 连续纳入2019年8月至2025年9月接受笔束扫描质子束再照射的乳腺癌孤立局部区域复发且既往剂量重叠的患者。
- 采用Fine-Gray模型评估临床/治疗因素与复发时间的关联,采用逻辑回归评估与≥2级不良事件的关联。
- 采用Kruskal-Wallis和Wilcoxon秩和检验评估DVH指标与晚期不良事件的相关性。
主要发现
- 中位首次疗程剂量、再照射疗程剂量和累积剂量分别为53 Gy(RBE)、50 Gy(RBE)和106 Gy(RBE)。
- 再照射期间82.2%的患者接受全面淋巴结照射。
- 中位随访30个月,2年和3年任意复发率分别为14%和17%,总生存率分别为100%和95%。
- 最大急性G2和G3不良事件发生率分别为50%和7%,晚期G2和G3分别为34%和10%。
- 肋骨骨折发生率为21.1%,与首次和再照射胸壁D200cc及首次肋骨D10cc相关。
关键数值与推荐
- 中位首次疗程剂量53 Gy(RBE)、再照射疗程剂量50 Gy(RBE)、累积剂量106 Gy(RBE)。
- 再照射期间82.2%接受全面淋巴结照射。
- 2年和3年任意复发率分别为14%和17%,总生存率分别为100%和95%。
- 急性G2和G3不良事件发生率分别为50%和7%,晚期G2和G3分别为34%和10%。
- 肋骨骨折发生率21.1%,与首次和再照射胸壁D200cc及首次肋骨D10cc相关。
临床怎么用
- 质子束再照射可用于乳腺癌孤立局部区域复发且既往剂量重叠的患者,以实现持久控制并预防进一步进展。
- 报告的剂量指标(如胸壁D200cc、肋骨D10cc)可作为再照射剂量约束的基础,用于患者选择和毒性预测。
局限性
- 剂量指标与不良事件的关联需在未来再照射研究中进一步细化验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with breast cancer isolated local-regional recurrence (iLRR) can benefit from salvage reirradiation (reRT) to provide durable control and prevent further progression. Conformal radiation techniques like pencil beam scanning (PBS) proton beam therapy (PBT) may improve the reRT therapeutic ratio by limiting cumulative dose and improving target region dose delivery. MATERIALS AND METHODS: Consecutive patients between 8/2019-9/2025 treated with PBS-PBT reRT for breast cancer iLRR with prior dose overlap were identified. Clinicopathologic, treatment, and outcomes details were collected. Associations between clinical/treatment factors and time to recurrence and grade (G) ≥2 adverse events (AEs) were evaluated with Fine-Gray models and logistic regression, respectively. Correlations between DVH metrics and late AEs were assessed using Kruskal-Wallis and Wilcoxon rank sum tests. RESULTS: Seventy patients were identified with median first course (C1), reRT course (C2), and cumulative doses of 53, 50, and 106Gy(RBE), respectively. During C2, 82.2% received comprehensive nodal irradiation. Median follow-up was 30 months. Two- and three-year rates of any recurrence were 14% and 17%, and OS were 100% and 95%, respectively. Maximum acute G2 and G3 AEs occurred in 50% and 7%, and late G2 and G3 AEs in 34% and 10%, respectively. Rib fractures developed in 21.1% and were associated with C1 and C2 chest wall D200cc and C1 rib D10cc. CONCLUSION: In the largest experience of PBT reRT for breast cancer iLRR to date, we report promising disease control and limited severe AEs despite a high-risk patient cohort. We provide dose metrics that can serve as the foundation for reRT dose constraints and be further refined in future reRT investigations.
引用
- Chakraborty MA, White C, Khan AJ, et al. Patient selection and toxicity predictors in proton reirradiation for locoregional breast cancer recurrence. Clin Transl Radiat Oncol. 2026. PMID: 42376234. doi:10.1016/j.ctro.2026.101218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。